Bionano Genomics

Operating Losses Will Curb Genomics Progress Yet Kindle Modest Recovery

AnalystLowTarget

Not Invested

Community Contributor

Published

19 Aug 25

AnalystLowTarget's Fair Value

US$8.00

74.5% undervalued

04 Sep

US$2.04

-92.2%

19.3%

-92.2%

19.3%

You can edit this narrative until Aug 19 10:08 PM. Then, changes will post as Updates.

Author's Valuation

US$874.5% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$8

74.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

24.39%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.45%

Calculation

US$17.44m

Earnings '28

6.14x

PE Ratio '28

US$107.07m

Market Cap '28

US$107.07m

Market Cap '28

10.28m

No. shares '28

US$10.41

Share Price '28

US$10.41 Share Price '28

Discounted to 2025 @ 9.18% p.a.

US$8.00

Fair Value '25